Better Prevention of Transmission and Lesion Development of Genital Herpes Predicted for AiCuris Drug AIC316
News Jul 24, 2012
AiCuris has announced that in depth analysis of data from the AIC316 Phase 2 trial in patients with genital herpes will be disclosed at several international meetings.
This information adds to the very favourable efficacy data meeting the primary endpoint of the trial which have already been announced. It further highlights the superiority of AIC316 in the treatment of genital herpes.
The reduction of shedding of genital herpes simplex virus (HSV) by AIC316 in the recent Phase 2 trial will be compared with data from clinical trials with nucleoside analogues.
AIC316, a HSV inhibitor with a novel mode of action and much improved half-life, shows superior reduction of shedding events associated with high viral load, which is regarded as clinically relevant for HSV lesion development and transmission.
AiCuris project leader Dr. Alexander Birkmann presents the data at the International Conference on Antiviral Research (ICAR) meeting in Sapporo, Japan, on 19th April 2012.
Furthermore, Professor Helga Rübsamen-Schaeff, CEO of AiCuris, gives an invited talk on AIC316 discussing this topic at the International Herpesvirus Workshop in Calgary, Canada, 4th-9th August 2012.
“Encouraged by this data the planning and preparation of the Phase 3 program is now underway with high priority” comments Dr. Marie Paule Richard, CMO of AiCuris.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE